A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Project: Research

Project Details

StatusActive
Effective start/end date8/10/24 → 7/10/26

Keywords

  • Clinical trials
  • BG-T187-101